By visiting our website or using services provided by Sai Life Sciences, you are accepting the practices described in the Privacy Policy.

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking “I Accept”, you confirm that you are above the age of 16, that you have read and understood the Cookies Usage and the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Sai Life in accordance with said policies.

I accept

Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2025.04.03

Sai Life Sciences sets up Peptide Research Center in India

Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.


Announcing the launch, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.”

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

Maneesh Pingle, Head of Discovery Services, said: “The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients’ evolving needs as they advance peptide therapies across diverse therapeutic areas."

The new Peptide Research Center will be integrated with Sai Life Sciences’ end-to-end discovery services, spanning synthetic and medicinal chemistry, biology, DMPK, and toxicology. This holistic approach ensures seamless transitions across different stages of drug discovery, accelerating timelines and enhancing success rates for peptide-based drug development.

By combining deep expertise, cutting-edge technology, and an integrated approach, Sai Life Sciences strengthens its commitment to supporting global clients in advancing innovative peptide therapeutics.

Share article

More News

2026.03.09

New Medicinal Chemistry block set for inauguration in Hyderabad

A new Medicinal Chemistry block, Unit VIII, is set for inauguration at IKP, Genome Valley, Hyderabad, expanding discovery capacity to meet growing program demand. The four-floor facility spans approximately 100,000 sq. ft. and is designed to support large, multi-disciplinary project teams. It accommodates more than 200 fume hoods and includes a tightly integrated analytical laboratory […]
Read more

2026.03.09

AI-enabled production and material planning platform implemented

Over the past several months, focused AI pilot initiatives have been conducted across operations to evaluate practical applications that strengthen execution. One such initiative is now live across the network: Optimus, an integrated AI-enabled production and material planning platform, implemented at the end of December 2025. Optimus consolidates capacity planning, equipment allocation, and material availability […]
Read more

2026.03.09

Commercial-scale Photo Flow Chemistry successfully executed in Bidar

Commercial-scale flow chemistry has been successfully executed at our API manufacturing site in Bidar for a late-phase program supporting a US-based innovator. This execution builds on prior investments in continuous processing infrastructure at the site, including a 3-litre photo flow reactor equipped with a monochromatic blue LED light source. The platform enables controlled photochemical transformations […]
Read more

2026.03.09

High-Throughput Experimentation platform goes live in Hyderabad

The High Throughput Experimentation (HTE) platform is now operational at our Integrated R&D Campus in Hyderabad, India. The system integrates automated experimental execution with structured data capture to support reproducible, high-quality screening and full traceability of results. Designed to evaluate multiple variables within a single experimental matrix, the platform enables rapid assessment of chemical space […]
Read more

2026.02.20

Sai Life Sciences to recruit 700+ professionals in FY27

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.The recruitment will span roles […]
Read more